These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 10858355)

  • 41. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG; Basuino L; Chambers HF
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activity of trovafloxacin (with or without ampicillin-sulbactam) against enterococci in an in vitro dynamic model of infection.
    Zinner SH; Gilbert D; Dudley MN
    Antimicrob Agents Chemother; 1998 Jan; 42(1):72-7. PubMed ID: 9449263
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to clinafloxacin.
    Harrington GD; Zarins LT; Ramsey MA; Bradley SF; Kauffman CA
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):27-31. PubMed ID: 7789094
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro and in vivo antibacterial activities of DW286, a new fluoronaphthyridone antibiotic.
    Yun HJ; Min YH; Lim JA; Kang JW; Kim SY; Kim MJ; Jeong JH; Choi YJ; Kwon HJ; Jung YH; Shim MJ; Choi EC
    Antimicrob Agents Chemother; 2002 Sep; 46(9):3071-4. PubMed ID: 12183275
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin.
    Cohen MA; Huband MD
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):43-6. PubMed ID: 9990475
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections.
    Hoogkamp-Korstanje JA
    J Antimicrob Chemother; 1997 Sep; 40(3):427-31. PubMed ID: 9338498
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.
    Chambers HF; Xiang Q; Liu ; Chow LL; Hackbarth C
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2742-6. PubMed ID: 10543757
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
    Nagura J; Kijima K; Kurazono M; Takahata S; Sugano T; Tanaka Y; Hirai Y; Yamada K; Takayama Y; Shitara E; Yonezawa M
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3526-8. PubMed ID: 16048975
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Imipenem therapy of experimental Staphylococcus aureus and Streptococcus faecalis endocarditis.
    Scheld WM; Keeley JM
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():65-78. PubMed ID: 6421794
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of sparfloxacin, temafloxacin, and ciprofloxacin for prophylaxis and treatment of experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
    Cagni A; Chuard C; Vaudaux PE; Schrenzel J; Lew DP
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1655-60. PubMed ID: 7486895
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Successful trovafloxacin prophylaxis against experimental streptococcal aortic valve endocarditis.
    Katsarolis I; Pefanis A; Iliopoulos D; Siaperas P; Karayiannakos P; Giamarellou H
    Antimicrob Agents Chemother; 2000 Sep; 44(9):2564-6. PubMed ID: 10952619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intraaortic vegetations and infective endocarditis.
    O'Sullivan CE
    N Engl J Med; 2007 Jun; 356(23):2430-1; author reply 2430-1. PubMed ID: 17561534
    [No Abstract]   [Full Text] [Related]  

  • 53. Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis.
    McGrath BJ; Kang SL; Kaatz GW; Rybak MJ
    Antimicrob Agents Chemother; 1994 Sep; 38(9):2034-40. PubMed ID: 7811015
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis.
    Kaatz GW; Seo SM; Barriere SL; Albrecht LM; Rybak MJ
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1547-50. PubMed ID: 1929325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Gilbert M; Boscia JA; Kobasa WD; Kaye D
    Antimicrob Agents Chemother; 1986 Mar; 29(3):461-3. PubMed ID: 3459391
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Parenteral sparfloxacin compared with ceftriaxone in treatment of experimental endocarditis due to penicillin-susceptible and -resistant streptococci.
    Entenza JM; Blatter M; Glauser MP; Moreillon P
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2683-8. PubMed ID: 7695248
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
    Firsov AA; Vasilov RG; Vostrov SN; Kononenko OV; Lubenko IY; Zinner SH
    J Antimicrob Chemother; 1999 Apr; 43(4):483-90. PubMed ID: 10350376
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampicillin-resistant Enterococcus faecium.
    Whitman MS; Pitsakis PG; Zausner A; Livornese LL; Osborne AJ; Johnson CC; Levison ME
    Antimicrob Agents Chemother; 1993 Oct; 37(10):2069-73. PubMed ID: 8257125
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative in-vitro activity of the new fluoroquinolone trovafloxacin (CP-99,219) against gram-positive cocci.
    Coque TM; Singh KV; Murray BE
    J Antimicrob Chemother; 1996 May; 37(5):1011-6. PubMed ID: 8737152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
    Miró JM; García-de-la-Mària C; Armero Y; de-Lazzari E; Soy D; Moreno A; del Rio A; Almela M; Mestres CA; Gatell JM; Jiménez-de-Anta MT; Marco F;
    Antimicrob Agents Chemother; 2007 Jul; 51(7):2373-7. PubMed ID: 17485502
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.